Send me real-time posts from this site at my email
Chris L

Sorrento's Accomplishments

Sorrento is a hot stock. $SRNE. What has it accomplished?

Lots. Set up a T2BF Account complete with $100,000. Pass all phases.

Then trade SRNE stock because:

1. PSS lawsuit worth $1.2 Billion+ potential

2. BARDA funding, other government funding

3.CYNK-001 NK FDA Phase 1/Phase 2 Trial data with Celularity (Sorrento has 25% stake)

4. STI-4398 (COVIDTRAP) FDA Phase 1 clinical trial

5. STI-1499 (COVIGUARD)FDA IND approval

6. COVISHIELD(Therapeutic cocktail in partnership with Mt. Sinai Hospital) FDA IND application

7. Preclinical, peer reviewed data publication on STI-1499 and STI-4398 from UTMB, Dr. Slobodan Paessler (anytime now).

8. I-Cell COVID 19 Vaccine IND approval

9. Sorrento and SmartPharm gene encoded vaccine IND application

10. Sorrento and MabPharma ACE MAB IND approval

11. Phase 1 trial data of CD 38 for Amyloidosis

12. SP-102 phase 3 results

13. CD38 lymphoma IND

14. RTX arthritis news

15. RTX knee pain news

16. RTX cancer pain news

17. RTX ARDS treatment

18. Scilex potential IPO

19. FDA approval of COVI-TRACK

20. Sales begin for COVI-TRACK

21. Several cancer trials with first-in-class DAR-T are coming

22. Abivirtinib phase 2 in Covid begins in August

23. Water soluble CBD partnership

24. Covid T-VIVA-19 Vaccine enters clinic

25. COVI-TRACE saliva test enters clinic

26. COVI-TRACE gains approval

27. SOFUSA delivery phase 1b cancer trial

28. Analysts target prices are increasing steadily. $30 is latest

29. Institutions are buying. Up from 18% to 26% this week alone

30. Insiders holding solid at 34%

$SRNE, Sorrento Therapeutics, Inc. / H1

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue